Mercator MedSystems, Inc.
Mercator MedSystems, Inc.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT | Deep Vein Thrombosis, Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-09-25 | NCT04862468 | |
| Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT | Embolism and Thrombosis, cardiovascular disorder, thrombotic disease, vascular disorder | Active, not recruiting | Phase 2 | 2026-06-25 | NCT04858776 | |
| Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee | Arterial Occlusive Diseases, Chronic Disease, Chronic Limb-Threatening Ischemia, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, ischemic disease, peripheral arterial disease, peripheral vascular disease, vascular disorder | Recruiting | Phase 3 | 2025-08-05 | NCT04433572 |